Adma Biologics reported $138.15M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Adma Biologics USD 138.15M 50.52M Mar/2026
Alnylam Pharmaceuticals USD 1.71B 53.53M Mar/2026
BioCryst Pharmaceuticals USD 171.59M 164.32M Mar/2026
Minerva Neurosciences USD 82.3M 70.02M Dec/2025
Novavax USD 228.36M 12.27M Mar/2026
Omeros USD 1.9M 2.36M Jun/2025
Takeda JPY 654.94B 26.55B Dec/2025